Cover Image
市場調查報告書

肺炎鏈球菌:開發中產品分析

Streptococcal Pneumonia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 362370
出版日期 內容資訊 英文 160 Pages
訂單完成後即時交付
價格
Back to Top
肺炎鏈球菌:開發中產品分析 Streptococcal Pneumonia - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 160 Pages
簡介

本報告提供肺炎鏈球菌治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

肺炎鏈球菌 (肺炎鏈球菌)的概要

治療藥的開發

肺炎鏈球菌:企業開發中的治療藥

肺炎鏈球菌:大學/機關研究中的治療藥

肺炎鏈球菌:開發中產品概況

肺炎鏈球菌:企業開發中的產品

肺炎鏈球菌:大學/機關研究中的產品

肺炎鏈球菌 (肺炎鏈球菌)的治療藥的開發企業

肺炎鏈球菌:治療藥的評估

藥物簡介

肺炎鏈球菌:最近的開發平台趨勢

肺炎鏈球菌:暫停中的計劃

肺炎鏈球菌:開發中止的產品

肺炎鏈球菌:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8822IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcal Pneumonia - Pipeline Review, H2 2016, provides an overview of the Streptococcal Pneumonia (Infectious Disease) pipeline landscape.

Pneumococcal infections are caused by the Streptococcus pneumoniae (S. pneumoniae) bacterium. They can be mild or severe. Symptoms include fever, chills, sweat, aches and pains. Risk factors include serious health condition, such as HIV or diabetes that weakens their immune system, taking medication that weakens their immune system, such as chemotherapy and age. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcal Pneumonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcal Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 6, 6, 2, 22, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 8 and 4 molecules, respectively.

Streptococcal Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Streptococcal Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Streptococcal Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Streptococcal Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Streptococcal Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Streptococcal Pneumonia Overview
  • Therapeutics Development
  • Streptococcal Pneumonia - Therapeutics under Development by Companies
  • Streptococcal Pneumonia - Therapeutics under Investigation by Universities/Institutes
  • Streptococcal Pneumonia - Pipeline Products Glance
  • Streptococcal Pneumonia - Products under Development by Companies
  • Streptococcal Pneumonia - Products under Investigation by Universities/Institutes
  • Streptococcal Pneumonia - Companies Involved in Therapeutics Development
  • Streptococcal Pneumonia - Therapeutics Assessment
  • Drug Profiles
  • Streptococcal Pneumonia - Dormant Projects
  • Streptococcal Pneumonia - Discontinued Products
  • Streptococcal Pneumonia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Streptococcal Pneumonia, H2 2016
  • Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Streptococcal Pneumonia - Pipeline by Abera Bioscience AB, H2 2016
  • Streptococcal Pneumonia - Pipeline by Actelion Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Affinivax Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Allergan Plc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Arsanis Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by AstraZeneca Plc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Biken Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by ContraFect Corp, H2 2016
  • Streptococcal Pneumonia - Pipeline by Crestone Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by FluGen Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Streptococcal Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Lascco SA, H2 2016
  • Streptococcal Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Merck & Co Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Mucosis BV, H2 2016
  • Streptococcal Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Pfizer Inc, H2 2016
  • Streptococcal Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016
  • Streptococcal Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016
  • Streptococcal Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Streptococcal Pneumonia - Pipeline by Valneva SE, H2 2016
  • Streptococcal Pneumonia - Pipeline by Vaxxilon AG, H2 2016
  • Streptococcal Pneumonia - Pipeline by Virometix AG, H2 2016
  • Streptococcal Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016
  • Streptococcal Pneumonia - Pipeline by Wockhardt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Streptococcal Pneumonia - Dormant Projects, H2 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..1), H2 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..2), H2 2016
  • Streptococcal Pneumonia - Dormant Projects (Contd..3), H2 2016
  • Streptococcal Pneumonia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Streptococcal Pneumonia, H2 2016
  • Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top